ZA201401776B - Antibodies to cd1d - Google Patents
Antibodies to cd1dInfo
- Publication number
- ZA201401776B ZA201401776B ZA2014/01776A ZA201401776A ZA201401776B ZA 201401776 B ZA201401776 B ZA 201401776B ZA 2014/01776 A ZA2014/01776 A ZA 2014/01776A ZA 201401776 A ZA201401776 A ZA 201401776A ZA 201401776 B ZA201401776 B ZA 201401776B
- Authority
- ZA
- South Africa
- Prior art keywords
- cd1d
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547307P | 2011-10-14 | 2011-10-14 | |
| AU2011904190A AU2011904190A0 (en) | 2011-10-14 | Antibodies to CD1d | |
| PCT/AU2012/001247 WO2013053021A1 (en) | 2011-10-14 | 2012-10-15 | ANTIBODIES TO CD1d |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201401776B true ZA201401776B (en) | 2016-01-27 |
Family
ID=48081279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/01776A ZA201401776B (en) | 2011-10-14 | 2014-03-11 | Antibodies to cd1d |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140286957A1 (https=) |
| EP (1) | EP2766042A4 (https=) |
| JP (1) | JP2015502915A (https=) |
| KR (1) | KR20140108520A (https=) |
| CN (1) | CN104144700B (https=) |
| AU (1) | AU2012323781B8 (https=) |
| BR (1) | BR112014008691A2 (https=) |
| CA (1) | CA2850961A1 (https=) |
| EA (1) | EA201400447A1 (https=) |
| IL (1) | IL231975A0 (https=) |
| MX (1) | MX2014004326A (https=) |
| SG (1) | SG11201400521PA (https=) |
| WO (1) | WO2013053021A1 (https=) |
| ZA (1) | ZA201401776B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| DK3440106T3 (da) * | 2016-04-08 | 2021-10-04 | Adaptimmune Ltd | T-cellereceptorer |
| SMT202200306T1 (it) * | 2016-04-08 | 2022-09-14 | Immunocore Ltd | Recettori di cellule t |
| BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| CN108079292A (zh) * | 2016-11-23 | 2018-05-29 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |
| EP4417210A1 (en) * | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
| SMT202500106T1 (it) * | 2020-08-18 | 2025-05-12 | Cephalon Llc | Anticorpi anti-par-2 e loro metodi d'uso |
| KR20230126714A (ko) * | 2020-12-18 | 2023-08-30 | 바이오아르디스 엘엘씨 | 메소텔린 결합 분자 및 이의 사용 |
| KR20250070621A (ko) | 2022-08-18 | 2025-05-20 | 이뮤노코어 리미티드 | Mage-a4에 특이적인 t 세포 수용체 융합 단백질 |
| CN116217704B (zh) * | 2022-10-25 | 2025-08-15 | 南京医科大学 | 一种抑制肝细胞凋亡的表面分子及其应用 |
| KR20250128342A (ko) * | 2022-12-21 | 2025-08-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 입양 면역요법을 위한 향상된 기능을 갖는 cd3 및 itcr을 발현하는 조작된 자연살해세포 |
| WO2024226794A1 (en) * | 2023-04-26 | 2024-10-31 | The Trustees Of Indiana University | Composition and methods for treatment of spinal cord injury and traumatic brain injury |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1095062B1 (en) * | 1998-07-09 | 2006-09-13 | Brian J. Nickoloff | Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| US8084020B2 (en) * | 2002-05-01 | 2011-12-27 | Beth Israel Deaconess Medical Center | Use of anti-CD1 antibodies for the modulation of immune responses |
| WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| US8012484B2 (en) * | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
-
2012
- 2012-10-15 SG SG11201400521PA patent/SG11201400521PA/en unknown
- 2012-10-15 KR KR1020147012848A patent/KR20140108520A/ko not_active Withdrawn
- 2012-10-15 WO PCT/AU2012/001247 patent/WO2013053021A1/en not_active Ceased
- 2012-10-15 BR BR112014008691A patent/BR112014008691A2/pt unknown
- 2012-10-15 EA EA201400447A patent/EA201400447A1/ru unknown
- 2012-10-15 AU AU2012323781A patent/AU2012323781B8/en not_active Ceased
- 2012-10-15 EP EP12840164.3A patent/EP2766042A4/en not_active Withdrawn
- 2012-10-15 MX MX2014004326A patent/MX2014004326A/es unknown
- 2012-10-15 CA CA2850961A patent/CA2850961A1/en not_active Abandoned
- 2012-10-15 JP JP2014534890A patent/JP2015502915A/ja active Pending
- 2012-10-15 CN CN201280050432.2A patent/CN104144700B/zh not_active Expired - Fee Related
-
2014
- 2014-03-11 ZA ZA2014/01776A patent/ZA201401776B/en unknown
- 2014-04-07 IL IL231975A patent/IL231975A0/en unknown
- 2014-04-10 US US14/249,566 patent/US20140286957A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ622050A (en) | 2016-07-29 |
| CN104144700A (zh) | 2014-11-12 |
| AU2012323781B2 (en) | 2015-04-23 |
| SG11201400521PA (en) | 2014-08-28 |
| JP2015502915A (ja) | 2015-01-29 |
| AU2012323781A1 (en) | 2014-03-27 |
| CN104144700B (zh) | 2016-10-19 |
| CA2850961A1 (en) | 2013-04-18 |
| AU2012323781B8 (en) | 2015-05-14 |
| BR112014008691A2 (pt) | 2017-06-13 |
| AU2012323781A8 (en) | 2015-05-14 |
| WO2013053021A1 (en) | 2013-04-18 |
| IL231975A0 (en) | 2014-05-28 |
| EP2766042A1 (en) | 2014-08-20 |
| MX2014004326A (es) | 2014-09-25 |
| EA201400447A1 (ru) | 2014-09-30 |
| EP2766042A4 (en) | 2015-05-27 |
| US20140286957A1 (en) | 2014-09-25 |
| KR20140108520A (ko) | 2014-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272035A (en) | Anti IL–36R antibodies | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| ZA201307983B (en) | Anti-b7-h3 antibody | |
| IL228001A0 (en) | Antibodies to 70cd | |
| IL231975A0 (en) | Antibodies to cd1d | |
| IL229254A0 (en) | Therapeutic antibodies | |
| IL230719A0 (en) | highly galactosylated antibodies | |
| IL232017A0 (en) | Antibodies of human origin to inkt | |
| EP2764325A4 (en) | USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| GB201121564D0 (en) | Use of antibody | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| PT2719842E (pt) | Reforço para utilização estrutural | |
| AU2011904190A0 (en) | Antibodies to CD1d | |
| GB201116456D0 (en) | Improvements relating to foorwear | |
| GB201100188D0 (en) | Structural members | |
| HUE041625T2 (hu) | Terápiás ellenanyagok |